Trade Mark Journal No.2026/044 30 October 2026
WO0000001943567 (1,5)
Office of origin: United States of America
Date of International Registration:12 July 2026
Date of designation in the UK:
12 July 2026
The mark consists of a fanciful design of a molecular structure made up of partial circles appearing to the left of the stylized word RADIANT, which appears above and offset to the word BIOTHERAPEUTICS; the grey and black shades appearing as fill color are not claimed as a feature of the mark.
International priority date claimed: 12 January 2026
(United States of America)
(99589951)
- Class 1
- Chemical, biochemical, biological, and biotechnological, preparations, namely, antibodies, bi- and multispecific antibodies as well as fragments, monovalent antibodies, derivatives of conjugates of any of these for in vitro and in vivo scientific and industrial research and development with regard to diseases; biochemicals, namely, monoclonal antibodies for in vivo or in vitro scientific research and development regarding cancer, AIDS (acquired immune deficiency syndrome), and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases.
- Class 5
- Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations based on antibodies, bi and multispecific antibodies as well as fragments, including monovalent antibodies, derivatives or conjugates of any of these for use with regard to the treatment of cancer, infectious, immune, autoimmune, inflammatory, neurodegenerative and cardiovascular diseases; pharmaceutical preparations based on human monoclonal antibodies for the treatment of cancer, AIDS (acquired immune deficiency syndrome) and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases.
Radiant Biotherapeutics
Representative: Tom M. Monagan Neal & McDevitt, LLC, 2801 Lakeside Drive, Suite 201, Bannockburn IL 60015, UNITED STATES OF AMERICA